 CAMBRIDGE, Mass., June 15, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicineTM SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934, an evolved strain of Synthetic Biotic medicine SYNB1618, for the treatment of Phenylketonuria PKU during the Synthetic Biology: Engineering, Evolution Design SEED conference, being held virtually June 15-18, 2021. 